Marta Vaz Batista, SABCS 2021: Preliminary Results From the DEBBRAH Phase II Study
Dr Marta Vaz Batista (Hospital Fernando Fonseca, Amadora, Portugal) discusses the preliminary results from the DEBBRAH phase II study, exploring trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement. These results were presented at the San Antonio Breast Cancer Symposium 2021.
Questions
1. Could you tell us a little about trastuzumab deruxtecan and its potential advantages over other trastuzumab antibody-drug conjugates? 00:20-01:49
2. What are the objectives of the DEBBRAH Phase II study? 01:49-02:55
3. Could you tell us a little about the study cohorts and eligibility criteria of the study? 02:55-03:58
4. What have been the preliminary findings of the study? 03:58-06:33
5. Where do you expect trastuzumab deruxtecan to sit in the treatment paradigm for HER2+ or HER2-low-expressing advanced breast cancer? 06:33-08:40
Speaker Disclosure: Marta Vaz Batista discloses honoraria from Daiichi Sankyo.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021